GET DAILY SIGNALSNephros (NEPH) Delivers 18% Revenue Growth in Q3 Despite Margin Headwinds
Key Takeaways
- Nephros reported third quarter 2026 net revenue of approximately $5.6 million, an 18% increase from $4.8 million in the prior-year period.
- Diluted earnings per share (EPS) came in at $0.05, up from $0.03 a year ago and ahead of the roughly $0.03 consensus estimate.
- Core programmatic revenue grew about 8% year over year, while the active customer base reached a record 1,766 sites.
- Gross margin eased to roughly 58% from 61%, reflecting tariffs, foreign exchange, freight costs, and a higher mix of lower-margin service revenue.
- Net income rose to approximately $0.5 million from $0.3 million, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) increased to about $0.6 million.
- The company remained debt-free with roughly $4.5 million in cash and cash equivalents as of September 30, 2026.
- For more detail on NEPH, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
- Discover automated market strategies on the Trending AI Robots page.
Why These Results Matter
NEPH is a commercial-stage water technology company focused on filtration solutions for medical and commercial markets. Its ultrafiltration products serve dialysis centers, hospitals, and hospitality settings. The latest quarterly update gives investors a clear view of demand trends in water-safety and infection-control products, a space that continues to expand beyond healthcare into broader commercial and industrial uses. This report is worth close attention because it shows whether the company can maintain its double-digit revenue growth while handling margin pressure from tariffs, currency movements, and a shift toward lower-margin services. With profitability now established and inclusion in the Russell Microcap Index this year, each update also tracks progress on its evolving products-services-education approach.
The Quarter in Detail
For the three months ended September 30, 2026, NEPH posted net revenue of about $5.6 million, up 18% from $4.8 million a year earlier. Product revenue reached roughly $5.4 million, while service, royalty, and other revenue totaled around $0.2 million. Core programmatic revenue rose about 8% year over year, and the active customer base expanded to a record 1,766 sites. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Net income came in at approximately $0.5 million, or $0.05 per diluted share, compared with $0.3 million, or $0.03 per diluted share, in the prior-year quarter. Adjusted EBITDA increased to about $0.6 million from roughly $0.4 million. Gross margin settled near 58%, down from 61%, as higher inventory, shipping, and tariff costs combined with faster growth in lower-margin service revenue.
Over the first nine months of 2026, net revenue grew 20% to around $16.9 million, core programmatic revenue advanced 19%, and net income rose to about $1.8 million. The company closed the quarter with roughly $4.5 million in cash and no debt.
Market Reaction and Sentiment
Shares of NEPH have remained under pressure over the past year even with steady revenue and profit gains. At the time of the report, the stock sat well below its 52-week high, posting double-digit declines over the trailing three- and twelve-month periods. The market seems focused on near-term margin compression and the modest float, while recognizing the improving profitability and debt-free balance sheet. Sentiment ahead of the release centered on the strength of recurring orders and whether gross margins could hold steady amid ongoing tariff and currency challenges. The earnings beat on the bottom line offered a positive signal, yet the modest gross-margin dip and the revenue mix shift toward services remain key points for the stock’s path forward.
Forward Outlook and Factors to Watch
NEPH heads into the end of 2026 with solid momentum in recurring revenue and a growing installed base. Management continues to emphasize three pillars—products, services, and education—with healthcare still the core market and commercial and industrial applications expanding. One thing that stands out is whether the record site count will drive sustained reorders that support the recurring model.
Margins will likely remain the biggest variable. Tariff costs, a softer dollar versus the euro, and higher shipping expenses continue to weigh on gross margin, while quicker growth in service and commercial product lines—both lower-margin than the core business—pulls the blended rate lower. Tracking whether gross margin stabilizes around current levels will help assess profitability trends ahead.
Additional items to monitor include adoption of newer products targeting PFAS, microplastics, and sterile processing, plus expansion in the Greater New York area and Puerto Rico. The cash position and debt-free balance sheet give room to support these efforts. Results should always be viewed against the company’s own filings rather than assumed quarterly patterns, given its fiscal year ends December 31.
My Experience With Tickeron’s AI Screener
I often turn to Tickeron’s AI Screener when analyzing small-cap names like this one. The tool lets me quickly filter stocks by industry, technical patterns, fundamentals, and AI signals to spot comparable setups or breakout candidates across the water technology and medical-device space. It has become a regular part of my research workflow for identifying ideas more efficiently than manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NEPH's Stochastic Oscillator stays in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NEPH's RSI Indicator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +3.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEPH advanced for three days, in 164 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
NEPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NEPH as a result. In 78 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for NEPH turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 33 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
The 10-day moving average for NEPH crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for NEPH entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 53 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.804) is normal, around the industry mean (5.069). P/E Ratio (19.312) is within average values for comparable stocks, (40.009). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.318) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. NEPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system
Industry PharmaceuticalsOther
Advertisement